




Canadian Immunodeficiencies Patient Organization

CIPO



GBS/CIDP  
Foundation of Canada



CANADIAN SOCIETY OF ALLERGY AND  
CLINICAL IMMUNOLOGY  
SOCIÉTÉ CANADIENNE D'ALLERGIE ET  
D'IMMUNOLOGIE CLINIQUE  
P.O. Box 51045, Orleans, ON K1E 3W4  
613 986 5869

Recommendations for the re-introduction of Cuvitru for patients requiring subcutaneous immunoglobulin for the first time (new starts).

The supply of Cuvitru is improving but not all patients requiring SCIG can yet be started. The recommendations are meant to allow for a graded reintroduction of new starts to try to prevent additional shortages.

These recommendations are not meant to replace clinical judgement and may not apply to all clinical situations.

We would recommend that patients who urgently require immunoglobulin therapy and are deemed candidates for SCIG that priority be given to those patients who cannot receive IVIG. Reasons that patients may be deemed unable to receive IVIG include any or all of the following:

- 1) Intravenous access is not possible or would require unnecessarily invasive means to achieve IV access.
- 2) The patient has had significant adverse reactions with IVIG products despite premedication.
- 3) Administration of IVIG is not feasible for a given site due to significant lack of resources such as nursing or clinic capacity.

These recommendations are not meant to replace clinical judgement and may not apply to all clinical situations.

Working Advisory Group on IG Supply



Handwritten signatures of Harold Kim, Donna Hartlen, Whitney Goulstone, and Bruce Ritchie.

Dr. Stephen Betschel, Co-Chair, Medical Science Advisory Committee, Canadian Immunodeficiencies Patient Organization

Whitney Goulstone, Executive Director, Canadian Immunodeficiencies Patient Organization

Donna Hartlen, Executive Director, GBS/CIDP Foundation of Canada

Dr. Hans Katzberg, Medical Advisor, GBS/CIDP Foundation of Canada

Dr. Harold Kim, President, Canadian Society of Allergy and Clinical Immunology

Dr. Bruce Ritchie, Co-Chair, Medical Science Advisory Committee, Canadian Immunodeficiencies Patient Organization

On behalf of:

Dr. Juthaporn Cowan, the Ottawa Hospital; Dr. Gina Lacuesta, Halifax; Dr. Steven Baker, McMaster University; Dr. Susan Wasserman, McMaster University; Dr. Zaeem Siddiqi, University of Alberta; Dr. Chrystina Kalicinsky, Winnipeg Health Sciences; Dr. Beata Derfalvi, IWK; Dr. Bill Cameron, Ottawa Hospital; Noor Nongfei Zhu, Fraser Health; Dr. Hakan Buyukdere, Ottawa Hospital; Dr. Robert Schellenberg, St. Paul's Hospital; Dr. Vera Bril, UHN